Adalimumab for the treatment of noninfectious uveitis has advantages over no treatment or conventional treatment with steroid therapy.
In this story, we revisit the clinical trials that led to the approval of adalimumab for uveitis.
Adalimumab improves function and quality of life for patients with uveitis, shows a study presented at 2015 ACR/ARHP.
A new tool could help ophthalmologists who see uveitis collaborate in the early diagnosis of spondyloarthritis.
Reports in a pediatric ophthalmology journal reveal risk factors and best treatments for refractory/recurrent uveitis in JIA.
The tumor necrosis factor α antagonist infliximab has been used for treating patients with uveitis resistant to corticosteroids.